Transforming Tumor Research: Engineering MHCs as Versatile Reagents

Transforming Tumor Research: Engineering MHCs as Versatile Reagents

Monday, April 15, 2024 3:00 PM to 3:20 PM · 20 min. (US/Pacific)
Cell Therapy
Presentation
Room 9

Information

  • In addressing solid tumors without specific biomarkers, the effectiveness of TCR-T cell therapy is hindered by the lack of reliable MHC reagents. 
  • To overcome this, we've developed versatile MHC molecules in different formats, such as peptide-ready, single-chain, and chimeric-MHC. These innovations offer convenient loading, enhanced sensitivity, and immunization capabilities. 
  • Our advancements, including fluorescent MHC-tetramers and MHC-VLPs, hold transformative potential in reshaping solid tumor studies by enabling more precise and effective R&D.
KACTUS517At KACTUS, our mission is to spearhead the biopharmaceutical and diagnostic industries by delivering novel recombinant proteins and enzymes. With an emphasis on innovation and quality, we excel in the design and production of premium-quality, high-activity recombinant proteins and enzymes. Our expertise covers a broad spectrum of applications, including antibody drug discovery, immunotherapy, gene therapy, and mRNA therapeutics. Our extensive catalog, boasting over 3,000 meticulously curated recombinant proteins, caters to a variety of targets, species, tags, and labels, ensuring we meet the diverse needs of scientists engaged in cutting-edge drug development. Each product in our selection is chosen for its ability to fulfill the unaddressed demands of the research community, with our commitment to quality and dependable supply at the forefront of our product approval process.

Log in